Results 161 to 170 of about 51,607 (296)

Treating Hematological Malignancies With OR‐2100, an Orally Bioavailable Prodrug of Decitabine

Cancer Science, Volume 116, Issue 4, Page 853-861, April 2025.
We have developed a silylated derivative of decitabine, OR‐2100, which is resistant to degradation by cytidine deaminase and orally bioavailable. In this article, we review the current status of DNA demethylating agents for treating hematological malignancies, with a focus on OR‐2100. ABSTRACT DNA methylation is an enzyme‐driven epigenetic modification
Tatsuro Watanabe, Keisuke Kidoguchi, Shinya Kimura   +2 more
wiley   +1 more source

In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia [PDF]

, 2002
Carlos M. Galmarini, Xavier Thomas, Fabien Calvo, Philippe Rousselot, Muriel Rabilloud, A Jaffari, Emeline Cros, Charles Dumontet   +7 more
openalex   +1 more source

Outcomes of Elderly Patients Admitted to the Intensive Care Unit for Newly Diagnosed Acute Myeloid Leukemia

European Journal of Haematology, Volume 114, Issue 4, Page 679-689, April 2025.
ABSTRACT Acute myeloid leukemias (AMLs) are the hematological malignancies with the highest need for intensive care unit (ICU) admission due to their association with various life‐threatening situations. Limited data exist regarding the outcomes of elderly individuals with AML admitted to the ICU.
Guillaume Berton, Marie‐Anne Hospital, Sylvain Garciaz, Camille Rouzaud, Valerio Maisano, Yosr Hicheri, Evelyne D'Incan Corda, Jerome Rey, Magali Bisbal, Antoine Sannini, Laurent Chow Chine, Luca Servan, Frederic Gonzalez, Norbert Vey, Djamel Mokart, Colombe Saillard   +15 more
wiley   +1 more source

Functional role of alternatively spliced deoxycytidine kinase in sensitivity to cytarabine of acute myeloid leukemic cells [PDF]

, 2002
Marjan J. T. Veuger, Mirjam H.M. Heemskerk, M. Willy Honders, Roel Willemze, Renée M. Y. Barge   +4 more
openalex   +1 more source

Cytarabine Crystals in CSF [PDF]

American Journal of Clinical Pathology, 2018
Stephanie Foster, Carlo Ledesma
openaire   +2 more sources

Comparison of HiDAC Versus FLAG‐IDA in the Treatment of Relapsed Acute Myeloid Leukemia and High‐Risk Myelodysplastic Syndrome

European Journal of Haematology, Volume 114, Issue 4, Page 620-625, April 2025.
ABSTRACT Background Relapsed acute myeloid leukemia (AML) and high‐risk myelodysplastic syndrome (HR‐MDS) are associated with a poor prognosis. It is unknown which re‐induction therapy provides the highest chance of durable remission. Commonly used therapies are high dose cytarabine (HiDAC) and triple therapy consisting of fludarabine, cytarabine, and ...
Man Wai Tang, Deborah Van der Tuin, Mesire Aydin, Jarom Heijmans, Arjan A. Van de Loosdrecht, Ellen Meijer, Caroline E. Rutten, Mariëlle Wondergem, Jeroen J. W. M. Janssen, Marjolein L. Donker, Mette D. Hazenberg, Sonja Zweegman, Bart J. Biemond, David C. De Leeuw, Erfan Nur   +14 more
wiley   +1 more source

Venetoclax with low-dose cytarabine, a forgotten combination in patients with acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review

Hematology, Transfusion and Cell Therapy
Background: Based on the VIALE-A and VIALE-C studies, the Food and Drug Administration approved venetoclax in 2020 in combination with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia ineligible for intensive ...
Lauro Fabián Amador-Medina, Erick Crespo-Solís, Francisco Javier Turrubiates-Hernández, Karla Edith Santibañez-Bedolla   +3 more
doaj  

Post-remission therapy of adult acute myeloid leukaemia: One cycle of high-dose versus standard-dose cytarabine

, 1997
M. Fopp, Martin F. Fey, M. Bacchi, F. Cavalli, J. Gmuer, E Jacky, L. Schmid, André Tichelli, A Tobler, L Tschopp, V von Fliedner, Aloïs Gratwohl   +11 more
openalex   +1 more source

Cyclopentenyl cytosine primes SK‐N‐BE(2)c neuroblastoma cells for cytarabine toxicity [PDF]

, 2002
Jörgen Bierau, Albert H. Gennip, René Leen, Jozien Helleman, Huib N. Caron, André B. P. Kuilenburg   +5 more
openalex   +1 more source

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.

The Lancet Haematology, 2016
A. Ferreri, K. Cwynarski, E. Pulczynski, M. Ponzoni, M. Deckert, L. Politi, V. Torri, C. Fox, P. Rosée, E. Schorb, A. Ambrosetti, Alexander Roth, C. Hemmaway, A. Ferrari, K. Linton, R. Rudà, M. Binder, T. Pukrop, M. Balzarotti, A. Fabbri, P. Johnson, J. Gørløv, G. Hess, J. Panse, F. Pisani, A. Tucci, S. Stilgenbauer, B. Hertenstein, U. Keller, S. Krause, A. Levis, H. Schmoll, F. Cavalli, J. Finke, M. Reni, E. Zucca, G. Illerhaus   +36 more
semanticscholar   +1 more source